Unique Mortality Profile in Japanese Patients with COPD: An Analysis from the Hokkaido COPD Cohort Study

References

• IshiiT, NishimuraM, AkimotoA, JamesMH, JonesP. Understanding low COPD exacerbation rates in Japan: a review and comparison with other countries. Int J Chron Obstruct Pulmon Dis. 2018;13:3459–3471. doi:10.2147/COPD.S16518730464435
   PubMed Web of Science ®Google Scholar
• FukuchiY, FernandezL, KuoHP, et al. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial. Respirology. 2011;16(5):825–835. doi:10.1111/j.1440-1843.2011.01982.x21539680
   PubMed Web of Science ®Google Scholar
• IchinoseM, TaniguchiH, TakizawaA, et al. The efficacy and safety of combined tiotropium and olodaterol via the Respimat® inhaler in patients with COPD: results from the Japanese sub-population of the Tonado® studies. Int J Chron Obstruct Pulmon Dis. 2016;11:2017–2027. doi:10.2147/COPD.S11038927621608
   PubMed Web of Science ®Google Scholar
• Summary tables of mortality estimates by cause, age and sex, by country, 2000–2016 [homepage on the Internet]. World Health Organization; 2018 Available from: https://www.who.int/healthinfo/grobal_burden_disease/estimates/en. Accessed 61, 2019.
   Google Scholar
• MakitaH, NasuharaY, NagaiK, et al. Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax. 2007;62(11):932–937. doi:10.1136/thx.2006.07277717573447
   PubMed Web of Science ®Google Scholar
• NishimuraM, MakitaH, NagaiK, et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(1):44–52. doi:10.1164/rccm.201106-0992OC22016444
   PubMed Web of Science ®Google Scholar
• SuzukiM, MakitaH, ItoYM, et al. Clinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort study. Eur Respir J. 2014;43(5):1289–1297. doi:10.1183/09031936.0011021324232696
   PubMed Web of Science ®Google Scholar
• SuzukiM, MakitaH, KonnoS, et al. Asthma-like features and clinical course of chronic obstructive pulmonary disease. An analysis from the Hokkaido COPD cohort study. Am J Respir Crit Care Med. 2016;194(11):1358–1365. doi:10.1164/rccm.201602-0353OC27224255
   PubMed Web of Science ®Google Scholar
• SuzukiM, MakitaH, KonnoS, et al. Annual change in FEV1 in elderly 10-year survivors with established chronic obstructive pulmonary disease. Sci Rep. 2019;9(1):2073. doi:10.1038/s41598-019-38659-830765818
   PubMed Web of Science ®Google Scholar
• Global strategy for the diagnosis, management, and prevention of COPD 2019 report [homepage on the Internet]. Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2018 Available from: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf. Accessed 61, 2019.
   Google Scholar
• HansellAL, WalkJA, SorianoJB. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur Respir J. 2003;22(5):809–814. doi:10.1183/09031936.03.0003140314621089
   PubMed Web of Science ®Google Scholar
• AnthonisenNR, SkeansMA, WiseRA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142(4):233–239. doi:10.7326/0003-4819-142-4-200502150-0000515710956
   PubMed Web of Science ®Google Scholar
• McGarveyLP, JohnM, AndersonJA, ZvarichM, WiseRA; TORCH Clinical Endpoint Committee. Ascertainment of cause-specific mortality in COPD: operations of the TORCH clinical endpoint committee. Thorax. 2007;62(5):411–415. doi:10.1136/thx.2006.07234817311843
   PubMed Web of Science ®Google Scholar
• McGarveyLP, MagderS, BurkhartD, et al. Cause-specific mortality adjudication in the UPLIFT® COPD trial: findings and recommendations. Respir Med. 2012;106(4):515–521. doi:10.1016/j.rmed.2011.10.00922100536
   PubMed Web of Science ®Google Scholar
• WiseRA, AnzuetoA, CottonD, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369(16):1491–1501. doi:10.1056/NEJMoa130334223992515
   PubMed Web of Science ®Google Scholar
• BerryCE, WiseRA. Mortality in COPD: causes, risk factors, and prevention. COPD. 2010;7(5):375–382. doi:10.3109/15412555.2010.51016020854053
   PubMedGoogle Scholar
• HarunaA, MuroS, NakanoY, et al. CT scan findings of emphysema predict mortality in COPD. Chest. 2010;138(3):635–640. doi:10.1378/chest.09-283620382712
   PubMed Web of Science ®Google Scholar
• ZhongN, MoonHS, LeeKH, et al. TIOtropium safety and performance in Respimat® (TIOSPIRTM): analysis of Asian cohort of COPD patients. Respirology. 2016;21(8):1397–1403. doi:10.1111/resp.1285627490162
   PubMed Web of Science ®Google Scholar
• IsoH. Lifestyle and cardiovascular disease in Japan. J Atheroscler Thromb. 2011;18(2):83–88. doi:10.5551/jat.686621307610
   PubMed Web of Science ®Google Scholar
• TomodaK, YoshikawaM, ItohT, et al. Elevated circulating plasma adiponectin in underweight patients with COPD. Chest. 2007;132(1):135–140. doi:10.1378/chest.07-022717625082
   PubMed Web of Science ®Google Scholar
• SuzukiM, MakitaH, ÖstlingJ, et al. Lower leptin/adiponectin ratio and risk of rapid lung function decline in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11(10):1511–1519. doi:10.1513/AnnalsATS.201408-351OC25372271
   PubMedGoogle Scholar
• KitamuraA, SatoS, KiyamaM, et al. Trends in the incidence of coronary heart disease and stroke and their risk factors in Japan, 1964 to 2003: the Akita-Osaka study. J Am Coll Cardiol. 2008;52(1):71–79. doi:10.1016/j.jacc.2008.02.07518582638
   PubMed Web of Science ®Google Scholar
• Global Health Data Exchange [homepage on the Internet]. GBD results tool. Available from: http://ghdx.healthdata.org/gbd-results-tool. Accessed 725, 2020.
   Google Scholar
• de TorresJP, MarínJM, CasanovaC, et al. Lung cancer in patients with chronic obstructive pulmonary disease– incidence and predicting factors. Am J Respir Crit Care Med. 2011;184(8):913–919. doi:10.1164/rccm.201103-0430OC21799072
   PubMed Web of Science ®Google Scholar
• Antonelli IncalziR, FusoL, De RosaM, et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J. 1997;10(12):2800–2974.
   Web of Science ®Google Scholar
• CelliBR, CoteCG, MartinJM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–1012. doi:10.1056/NEJMoa02132214999112
   PubMed Web of Science ®Google Scholar
• DivoM, CoteC, de TorresJP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155–161. doi:10.1164/rccm.201201-0034OC22561964
   PubMed Web of Science ®Google Scholar
• RuggieroC, MetterEJ, MelenovskyV, et al. High basal metabolic rate is a risk factor for mortality: the Baltimore longitudinal study of aging. J Gerontol a Biol Sci Med Sci. 2008;63(7):698–706. doi:10.1093/gerona/63.7.69818693224
   PubMed Web of Science ®Google Scholar
• AlleyDE, MetterEJ, GriswoldME, et al. Changes in weight at the end of life: characterizing weight loss by time to death in a cohort study of older men. Am J Epidemiol. 2010;172(5):558–565. doi:10.1093/aje/kwq16820682520
   PubMed Web of Science ®Google Scholar